Articles
16 June 2009
Vol. 1 No. 3: von Willebrand disease: an update 80 years after its first description
https://doi.org/10.4081/hmr.v1i3.621

The role of FVIII/VWF concentrates in the treatment of von Willebrand diseasel

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
239
Views
1518
Downloads

Authors

Massimo Morfini
support@pagepress.org
Two are the goals of treatment of bleeding episodes in patients with von Willebrand disease (VWD): to correct the abnormal platelet adhesion due to reduced and/or dysfunctional von Willebrand Factor (VWF) and to increase the low level of Factor VIII (FVIII). Replacement therapy with plasma-derived FVIII/VWF concentrates is required for VWD patients who do not respond to desmopressin. Several factors should be taken into account to design and optimize the replacement therapy of VWD. As for other inherited bleeding disorders, the choice of a specific treatment requires an accurate diagnosis, which is of a particular relevance in VWD because of the heterogeneity of phenotypes.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



The role of FVIII/VWF concentrates in the treatment of von Willebrand diseasel. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(3). https://doi.org/10.4081/hmr.v1i3.621